Advances in pharmacotherapy for treating endometriosis

Emanuela Tafi, Umberto Leone Roberti Maggiore, Franco Alessandri, Stefano Bogliolo, Barbara Gardella, Valerio Gaetano Vellone, Federica Grillo, Luca Mastracci, Simone Ferrero

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Introduction: Endometriosis is an estrogen-dependent chronic disease requiring long-term therapy. Therefore, the choice of medical treatment should be based on efficacy, preference of patients, incidence and severity of adverse effects and cost.Areas covered: This review briefly summarizes the currently available medical treatment for endometriosis. The treatments most recently proposed for endometriosis will be described in detail, including gonadotropin-releasing hormone (GnRH) antagonists, aromatase inhibitors (AIs) and the flexible extended combined oral contraceptive.Expert opinion: The oral contraceptive pill and progestogens allow for the treatment of the majority of patients with endometriosis. The flexible extended dosing regimen, containing drospirenone and ethinylestradiol, may be particularly useful in patients suffering severe dysmenorrhea and improving the adherence and compliance with treatment. GnRH agonists may be used in patients resistant to first-line therapy; up to now, limited data are available on the use of GnRH antagonist (such as elagolix) in patients with endometriosis. AIs should be regarded as experimental therapies and used only in patients with symptoms resistant to other therapies; however, the use of these drugs is limited by the possibility to administer the treatment for short-term periods only (6 months) and, similarly to GnRH antagonists, by the high incidence of adverse effects, requiring the use of add-back therapy.

Original languageEnglish
Pages (from-to)2465-2483
Number of pages19
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number16
DOIs
Publication statusPublished - Nov 2 2015

Fingerprint

Endometriosis
Drug Therapy
Hormone Antagonists
Gonadotropin-Releasing Hormone
Therapeutics
Aromatase Inhibitors
Contraceptives, Oral, Combined
Dysmenorrhea
Investigational Therapies
Ethinyl Estradiol
Patient Preference
Incidence
Expert Testimony
Progestins
Oral Contraceptives
Estrogens
Chronic Disease
Costs and Cost Analysis

Keywords

  • aromatase inhibitors
  • endometriosis
  • flexible extended combined oral contraceptive
  • gonadotropin-releasing hormone antagonist

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Advances in pharmacotherapy for treating endometriosis. / Tafi, Emanuela; Leone Roberti Maggiore, Umberto; Alessandri, Franco; Bogliolo, Stefano; Gardella, Barbara; Vellone, Valerio Gaetano; Grillo, Federica; Mastracci, Luca; Ferrero, Simone.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 16, 02.11.2015, p. 2465-2483.

Research output: Contribution to journalArticle

Tafi, Emanuela ; Leone Roberti Maggiore, Umberto ; Alessandri, Franco ; Bogliolo, Stefano ; Gardella, Barbara ; Vellone, Valerio Gaetano ; Grillo, Federica ; Mastracci, Luca ; Ferrero, Simone. / Advances in pharmacotherapy for treating endometriosis. In: Expert Opinion on Pharmacotherapy. 2015 ; Vol. 16, No. 16. pp. 2465-2483.
@article{3da8ca2681934f41a2a024978b2d8b91,
title = "Advances in pharmacotherapy for treating endometriosis",
abstract = "Introduction: Endometriosis is an estrogen-dependent chronic disease requiring long-term therapy. Therefore, the choice of medical treatment should be based on efficacy, preference of patients, incidence and severity of adverse effects and cost.Areas covered: This review briefly summarizes the currently available medical treatment for endometriosis. The treatments most recently proposed for endometriosis will be described in detail, including gonadotropin-releasing hormone (GnRH) antagonists, aromatase inhibitors (AIs) and the flexible extended combined oral contraceptive.Expert opinion: The oral contraceptive pill and progestogens allow for the treatment of the majority of patients with endometriosis. The flexible extended dosing regimen, containing drospirenone and ethinylestradiol, may be particularly useful in patients suffering severe dysmenorrhea and improving the adherence and compliance with treatment. GnRH agonists may be used in patients resistant to first-line therapy; up to now, limited data are available on the use of GnRH antagonist (such as elagolix) in patients with endometriosis. AIs should be regarded as experimental therapies and used only in patients with symptoms resistant to other therapies; however, the use of these drugs is limited by the possibility to administer the treatment for short-term periods only (6 months) and, similarly to GnRH antagonists, by the high incidence of adverse effects, requiring the use of add-back therapy.",
keywords = "aromatase inhibitors, endometriosis, flexible extended combined oral contraceptive, gonadotropin-releasing hormone antagonist",
author = "Emanuela Tafi and {Leone Roberti Maggiore}, Umberto and Franco Alessandri and Stefano Bogliolo and Barbara Gardella and Vellone, {Valerio Gaetano} and Federica Grillo and Luca Mastracci and Simone Ferrero",
year = "2015",
month = "11",
day = "2",
doi = "10.1517/14656566.2015.1085510",
language = "English",
volume = "16",
pages = "2465--2483",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "16",

}

TY - JOUR

T1 - Advances in pharmacotherapy for treating endometriosis

AU - Tafi, Emanuela

AU - Leone Roberti Maggiore, Umberto

AU - Alessandri, Franco

AU - Bogliolo, Stefano

AU - Gardella, Barbara

AU - Vellone, Valerio Gaetano

AU - Grillo, Federica

AU - Mastracci, Luca

AU - Ferrero, Simone

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Introduction: Endometriosis is an estrogen-dependent chronic disease requiring long-term therapy. Therefore, the choice of medical treatment should be based on efficacy, preference of patients, incidence and severity of adverse effects and cost.Areas covered: This review briefly summarizes the currently available medical treatment for endometriosis. The treatments most recently proposed for endometriosis will be described in detail, including gonadotropin-releasing hormone (GnRH) antagonists, aromatase inhibitors (AIs) and the flexible extended combined oral contraceptive.Expert opinion: The oral contraceptive pill and progestogens allow for the treatment of the majority of patients with endometriosis. The flexible extended dosing regimen, containing drospirenone and ethinylestradiol, may be particularly useful in patients suffering severe dysmenorrhea and improving the adherence and compliance with treatment. GnRH agonists may be used in patients resistant to first-line therapy; up to now, limited data are available on the use of GnRH antagonist (such as elagolix) in patients with endometriosis. AIs should be regarded as experimental therapies and used only in patients with symptoms resistant to other therapies; however, the use of these drugs is limited by the possibility to administer the treatment for short-term periods only (6 months) and, similarly to GnRH antagonists, by the high incidence of adverse effects, requiring the use of add-back therapy.

AB - Introduction: Endometriosis is an estrogen-dependent chronic disease requiring long-term therapy. Therefore, the choice of medical treatment should be based on efficacy, preference of patients, incidence and severity of adverse effects and cost.Areas covered: This review briefly summarizes the currently available medical treatment for endometriosis. The treatments most recently proposed for endometriosis will be described in detail, including gonadotropin-releasing hormone (GnRH) antagonists, aromatase inhibitors (AIs) and the flexible extended combined oral contraceptive.Expert opinion: The oral contraceptive pill and progestogens allow for the treatment of the majority of patients with endometriosis. The flexible extended dosing regimen, containing drospirenone and ethinylestradiol, may be particularly useful in patients suffering severe dysmenorrhea and improving the adherence and compliance with treatment. GnRH agonists may be used in patients resistant to first-line therapy; up to now, limited data are available on the use of GnRH antagonist (such as elagolix) in patients with endometriosis. AIs should be regarded as experimental therapies and used only in patients with symptoms resistant to other therapies; however, the use of these drugs is limited by the possibility to administer the treatment for short-term periods only (6 months) and, similarly to GnRH antagonists, by the high incidence of adverse effects, requiring the use of add-back therapy.

KW - aromatase inhibitors

KW - endometriosis

KW - flexible extended combined oral contraceptive

KW - gonadotropin-releasing hormone antagonist

UR - http://www.scopus.com/inward/record.url?scp=84947485987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947485987&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1085510

DO - 10.1517/14656566.2015.1085510

M3 - Article

C2 - 26569155

AN - SCOPUS:84947485987

VL - 16

SP - 2465

EP - 2483

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -